The introduction of new technologies for insulin therapy and glycemic control in clinical practice in the period 2016-2023, and their impact on achieving treatment targets in children with type 1 diabetes mellitus

BACKGROUND : continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) improve daily life for people with Type 1 Diabetes Mellitus dramatically (T1D). However, there are still no compelling evidences that the use of insulin pumps (IP) and continuous glucose monitors (CGM) really help to improve diabetes control in children and adolescents. AIM: to analyze the relation between diabetes control and the use of insulin pumps and continuous glucose monitors in children. MATERIALS AND METHODS: 6382 children with T1D aged 1–18 years were enrolled in this study. Frequency of CSII and CGM use, HbA 1 с level and the percentage of children with HbA 1 с < 7.0% were analyzed. RESULTS: HbA 1c decreased from 8.6% to 7.7% for 7 years (p<0.001). Simultaneously the quantity of children with HbA 1c <7.0% increased from 11% to 29%. During this period the use of CGM increases dramatically from 11.6% to 84%. The use of IP increases from 38.7% to 42.3% (p<0.001). CONCLUSION : CSII and continuous glucose monitors use statistically significant improves T1D control in children according to mean HbA 1c level decrease and the quantity of children with target HbA 1c level increase.